Free Trial
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free POLB Stock Alerts

Poolbeg Pharma (POLB) Competitors

Poolbeg Pharma logo
GBX 8.05 -0.55 (-6.40%)
As of 12:38 PM Eastern
Compare

POLB vs. ARIX, CIR, TILS, VSN, and FARN

Should you buy Poolbeg Pharma stock or one of its competitors? MarketBeat compares Poolbeg Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Poolbeg Pharma include Arix Bioscience (ARIX), Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), and Faron Pharmaceuticals Oy (FARN). These companies are all part of the "biotechnology" industry.

How does Poolbeg Pharma compare to Arix Bioscience?

Poolbeg Pharma (LON:POLB) and Arix Bioscience (LON:ARIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Arix Bioscience has a net margin of 105.64% compared to Poolbeg Pharma's net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Arix Bioscience 105.64%6.41%2.18%

Poolbeg Pharma has a beta of 1.775, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

1.5% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are held by institutional investors. 7.6% of Poolbeg Pharma shares are held by insiders. Comparatively, 20.7% of Arix Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Arix Bioscience has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
Arix Bioscience£14.16M0.00£14.96M£0.11N/A

In the previous week, Poolbeg Pharma had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for Poolbeg Pharma and 0 mentions for Arix Bioscience. Poolbeg Pharma's average media sentiment score of 0.75 beat Arix Bioscience's score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Poolbeg Pharma Positive
Arix Bioscience Neutral

Summary

Arix Bioscience beats Poolbeg Pharma on 9 of the 12 factors compared between the two stocks.

How does Poolbeg Pharma compare to Circassia Group?

Circassia Group (LON:CIR) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

1.5% of Poolbeg Pharma shares are owned by institutional investors. 7.6% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Circassia Group has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Circassia Group£27.90M0.00N/A£0.01N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

Circassia Group's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Circassia GroupN/A N/A N/A
Poolbeg Pharma N/A -55.47%-21.33%

In the previous week, Poolbeg Pharma had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for Poolbeg Pharma and 0 mentions for Circassia Group. Poolbeg Pharma's average media sentiment score of 0.75 beat Circassia Group's score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Circassia Group Neutral
Poolbeg Pharma Positive

Summary

Circassia Group beats Poolbeg Pharma on 5 of the 9 factors compared between the two stocks.

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Poolbeg Pharma (LON:POLB) and Tiziana Life Sciences (LON:TILS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

1.5% of Poolbeg Pharma shares are held by institutional investors. 7.6% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tiziana Life Sciences has lower revenue, but higher earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A

Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Tiziana Life Sciences N/A N/A N/A

In the previous week, Poolbeg Pharma had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 1 mentions for Poolbeg Pharma and 0 mentions for Tiziana Life Sciences. Poolbeg Pharma's average media sentiment score of 0.75 beat Tiziana Life Sciences' score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Poolbeg Pharma Positive
Tiziana Life Sciences Neutral

Summary

Poolbeg Pharma beats Tiziana Life Sciences on 6 of the 9 factors compared between the two stocks.

How does Poolbeg Pharma compare to Verseon?

Verseon (LON:VSN) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

In the previous week, Poolbeg Pharma had 1 more articles in the media than Verseon. MarketBeat recorded 1 mentions for Poolbeg Pharma and 0 mentions for Verseon. Poolbeg Pharma's average media sentiment score of 0.75 beat Verseon's score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Verseon Neutral
Poolbeg Pharma Positive

Verseon's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
VerseonN/A N/A N/A
Poolbeg Pharma N/A -55.47%-21.33%

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VerseonN/AN/AN/A-£14.30N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

1.5% of Poolbeg Pharma shares are owned by institutional investors. 7.6% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Poolbeg Pharma beats Verseon on 5 of the 8 factors compared between the two stocks.

How does Poolbeg Pharma compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

In the previous week, Faron Pharmaceuticals Oy had 3 more articles in the media than Poolbeg Pharma. MarketBeat recorded 4 mentions for Faron Pharmaceuticals Oy and 1 mentions for Poolbeg Pharma. Faron Pharmaceuticals Oy's average media sentiment score of 0.85 beat Poolbeg Pharma's score of 0.75 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Faron Pharmaceuticals Oy
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Poolbeg Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are held by institutional investors. 2.8% of Faron Pharmaceuticals Oy shares are held by insiders. Comparatively, 7.6% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 45.13% -70.00%
Poolbeg Pharma N/A -55.47%-21.33%

Faron Pharmaceuticals Oy has a beta of 1.109, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.775, suggesting that its share price is 78% more volatile than the broader market.

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

Summary

Faron Pharmaceuticals Oy beats Poolbeg Pharma on 6 of the 10 factors compared between the two stocks.

Get Poolbeg Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

POLB vs. The Competition

Export
MetricPoolbeg PharmaBiotechnology IndustryMedical SectorLON Exchange
Market Cap£56.76M£440.76M£6.44B£2.74B
Dividend YieldN/A3.86%2.67%6.16%
P/E Ratio-8.563.2023.80366.44
Price / SalesN/A6,461.99479.3587,084.66
Price / Cash2.1113.1326.9927.85
Price / Book0.0085.1110.367.67
Net Income-£4.50B-£96.07M£3.57B£5.89B
7 Day Performance22.71%-2.02%-1.27%-0.94%
1 Month Performance87.73%1.18%3.17%1.56%
1 Year Performance136.76%64.77%23.59%72.42%

Poolbeg Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
POLB
Poolbeg Pharma
N/AGBX 8.05
-6.4%		N/A+152.9%£56.76MN/AN/A12
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:POLB) was last updated on 6/8/2026 by MarketBeat.com Staff.
From Our Partners
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...
Porter & Company | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel
BNZI Breakout Watch: AI Growth Meets Turnaround Setup!
Banzai International (NASDAQ: BNZI) posted full-year 2025 revenue of $12.2 million, up 169% year-over-year, wi...
Huge Alerts | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
In 30 days, you'll wish you'd read this email
A small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel